Verbatim): The hypothesis of this proposal is that a thrombin inhibitor that selectively interferes with platelet activation will be an important therapeutic agent in the management of acute coronary syndromes. Thromgen, Inc. is developing a class of agents called thrombostatin as antithrombin, anti-platelet drugs to be used for heart attacks and interventional cardiovascular procedures. Thrombostatin prevents a-thrombin from activating platelets. It is a bifunctional inhibitor that weakly interacts with thrombin' s active site and more tightly interacts with thrombin's receptor, protease-activated receptor 1 (PAR 1). Thrombostatin is a novel platelet-selective thrombin inhibitor.
The specific aims of this proposal are as follows:
Specific Aim #1 : Studies will be done to prepare more potent and selective inhibitors of thrombin activation of PAR1 by empiric synthesis and rational drug design.
Specific Aim #2 : The antithrombotic ability of thrombostatin and platelet glycoprotein IIb/IIIa antagonists will be compared in dogs. These investigations will result in the development of a novel class of platelet-selective thrombin inhibitors to prevent arterial thrombosis. These investigations also will result in a new therapeutic approach to the management of patients with acute coronary syndromes.
Not Available
| Schmaier, Alvin H (2010) Oscar D. Ratnoff: a man for all seasons. Thromb Haemost 104:863-6 |
| Schmaier, Alec A; Schmaier, Alvin H (2009) Thrombosis in flowing blood. Blood 114:754-6 |
| Nieman, Marvin T; Schmaier, Alvin H (2007) Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 46:8603-10 |
